Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct
pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the
specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally
prevent the progressive beta cell failure and development of overt type 2 diabetes.
Phase:
N/A
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborators:
American Diabetes Association AstraZeneca National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)